XML 32 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Revenues
 9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
REVENUES REVENUES
Product Revenues
The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018.
The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2021 and 2020:
Three months ended September 30,Nine months ended September 30,
2021202020212020
Products:
Kristalose$4,012,746 $3,615,557 $12,286,729 $10,387,046 
Vibativ1,896,584 2,813,249 8,799,891 8,551,125 
Caldolor1,255,669 1,416,146 3,734,273 3,677,434 
Vaprisol325,774 406,162 1,861,130 790,817 
Acetadote368,733 218,462 638,704 1,527,173 
Omeclamox-Pak22,689 516,066 (451,683)640,435 
RediTrex11,459 — (13,291)— 
Other revenue178,886 265,047 809,429 1,605,570 
Total net revenues$8,072,540 $9,250,689 $27,665,182 $27,179,600 

The Omeclamox-Pak revenue for the first, second and third quarter of 2021 was the result of Cumberland currently being out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19. They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing. In the third quarter of 2021, the amounts noted were normal adjustments by channel partners. Net revenue was negatively impacted by product returns during the periods.

Other Revenues
The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner’s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies. The contractual payments associated with the partner’s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.
Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET’s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.02 million and $0.1 million for the three months ended September 30, 2021 and 2020